Magazine article Drug Topics

New SSRI Touts Fewer Side Effects

Magazine article Drug Topics

New SSRI Touts Fewer Side Effects

Article excerpt


Low prices and heavy promotion, plus a solid clinical profile, will make escitalopram oxalate (Lexapro) a blockbuster for Forest Laboratories, according to several financial analysts. Health professionals say escitalopram's early onset of antidepressant action (starting at one to two weeks) could be advantageous, if clinical experience shows such onset commonly occurs.

The Food & Drug Administration first approved escitalopram for the treatment of major depression in mid-August. Two weeks later, it OK'd another indication-as maintenance treatment for major depression. The selective serotonin reuptake inhibitor (SSRI) already has approval in several European rn countries to treat panic disorder with or without agoraphobia. Studies show escitalopram also works for social anxiety disorder and general anxiety disorder.

Forest seems intent on ensuring that people give up escitalopram's parent drug, racemic citalopram (Celexa), and switch to escitalopram, the active isomer of citalopram, before citalopram's US. patent expires in January 2004. A company spokesman said escitalopram would cost slightly less than citalopram, which Forest will continue to manufacture but will not promote.

However, the British edition of reported in mid-August that Forest and the Danish company H. Lundbeck (the original developer) "recently have been [marketing] Celexa in pediatrics and now compulsive shopping sufferers. The strategy is to extend the patent of Celexa while still differentiating it from Lexapro." Forest needs a big success with escitalopram and/or continuing income from citalopram because the $1 billion in citalopram sales is almost 70% of Forest's revenues.

"Lexapro is a welcomed treatment option because it offers many patients relief from depression symptoms quickly, with few side effects and a low risk of drug interactions," said Jack Gorman, M.D., professor and vice chair for research of the Department of Psychiatry, College of Physicians and Surgeons, Columbia University.

"Almost every new antidepressant has claimed the same thing [e.g., fewer side effects, earlier efficacy]. But they actually have different, not fewer, side effects," said Dan Still, clinical pharmacologist at the San Antonio State Hospital and clinical professor of pharmacy at the University of Texas Health Science Center. As for early onset, it simply takes time for SSRIs to downregulate receptors. The early-onset effects in studies often are anxiolytic or sedative, he said.

Voicing the wait-and-see attitude common among clinicians when a new drug appears, Still added that escitalopram is not revolutionary. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.